Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.
Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...
Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...
Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).
Genentech plans to expand the label for its CD20-targeting antibody Gazyva following positive late-stage data in ...
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for ...
Adicet Bio (ACET – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from ...
After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan ...
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit Genentech announced Thursday that Gazyva, a lymphoma therapy it co-develops with ...
The Taliban say it's absurd to accuse them of gender discrimination and other human rights violations, as four countries vow ...
(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback